ClinicalTrials.gg
CompletedNCT02582840Updated Jan 18, 2019Results posted

The PK and PD of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM

A Phase 1 interventional study of Dapagliflozin 5mg and Dapagliflozin 10mg in Type 1 Diabetes Mellitus, sponsored by AstraZeneca. Completed at 1 site in Japan. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-01-18.

Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 23 studies testing dapagliflozin in Diabetes Mellitus, Type 1 — 2 open to participants now, 5 under way, 2 of them phase 3. dapagliflozin · Diabetes Mellitus, Type 1.

Enrollment
13th of 23
42 · median 43
Started
2015
with 3 others
Phase 1
5 of 23
none open now
Registered
6th of 23
by date
Lead sponsor
5 of 23
AstraZeneca

Among the 23 studies testing dapagliflozin in Diabetes Mellitus, Type 1, this one is the 13th largest by enrollment, is one of 4 that started in 2015, is one of 5 in phase 1, and was the 6th registered.

Diabetes Mellitus, Type 1

3,756 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

2 of the 23 studies testing dapagliflozin in Diabetes Mellitus, Type 1 are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About dapagliflozin

dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 65 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing dapagliflozin in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

This randomized, single-blind, 3 arm, parallel group, placebo controlled PK/PD study will enrol 30 Japanese male and female patients with T1DM and age 18 to 65 years, with inadequate glycemic control on insulin defined as HbA1c ≥ 7.0% and ≤ 10.0% at screening visit. lacebo-controlled design. Patients will be randomized in a 1:1:1 ratio into one of the 3 single-blinded treatment arms; dapagliflozin 5 mg, dapagliflozin 10 mg or placebo. CSII user are excluded.

03

Conditions studied

  • Type 1 Diabetes Mellitus

Keywords

  • Japanese patients with type 1 diabetes with inadequate glycemic control on insulin
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed Written Subjects or their legally responsible representatives must be willing and able to give signed and dated written informed consent.
  • Target Population Diagnosis of T1DM. In addition, the following criteria also needs to be met; Central laboratory test of C-peptide \< 0.7 ng/mL Subject re-enrolment: This study does not permit the re-enrolment of a subject who has discontinued the study as a screen failure
  • Insulin use for at least 12 months prior to the enrolment per subject report or medical records and Method of insulin administration (MDI) must have been unchanged for at least 3 months prior to the enrolment per subject report or medical records. Subjects must be taking a total daily insulin dose of ≥ 0.3 U/kg/day for at least 3 months prior to the enrolment. CSII users are excluded. MDI insulin administration subject must be on ≥ 3x injections per day.
  • Gender and reproductive Status Japanese men and women.
  • eligibility criteria include: Screening Visit: Central laboratory HbA1c ≥ 7.0 % and ≤ 10.0 % (One repeat HbA1c test for subjects in screening if their initial test result was an HbA1c ± 0.2% of the cut off values)
  • ≥ 20.0 kg/m², ≤ 35.0 kg/m² at visit 1
  • Ages 18 to 65 years, inclusive - ≥ 18 years old and \< 20 years old must have assent forms signed and dated by their parents or guardians

Exclusion criteria

Exclusion Criteria:

  • Target Disease Exceptions History of T2DM In cases where the subject has a history of T2DM and has a documented history of being auto-antibody positive for GAD65, tyrosine phosphatase IA-2/IA-2β, or Zinc Transporter 8 (ZnT8), or fasting c-peptide value below the lower limit of detection performed by local or central laborator, the subject will be eligible for screening
  • Maturity onset diabetes of young (MODY), Pancreatic surgery, chronic pancreatitis, or other pancreatic disorders that could result in decreased β-cell capacity (eg, pancreatogenous diabetes)
  • Any antihyperglycemic agent use, other than thiazolidinediones, or insulin, within 1 month prior to the screening visit. Use of thiazolidinediones within 6 months prior to the screening visit.
  • History of DKA requiring medical intervention (eg, emergency room visit and/or hospitalization) within 1 month prior to the enrolment
  • History of hospital admission for glycemic control (either hyperglycemia or hypoglycemia) within 1 month prior to the enrolment
  • within 5 years of the enrolment (with the exception of treated basal cell or treated squamous cell carcinoma)
  • History of bladder cancer
  • History of radiation therapy to the lower abdomen or pelvis at any time Unstable pre-proliferative and proliferative retinopathy (untreated or under treatment).
  • Physical and Laboratory Test Findings (AST) > 3x (ULN) Alanine aminotransferase (ALT) > 3x ULN Serum total (TB) > 2.0 mg/dL (34.2 μmol/L).
  • Estimated (eGFR) by the Japanese Society of Nephrology formula ≤ 60 mL/min/1.73m2. ≤ 11.0 g/dL (110 g/L) for men; hemoglobin ≤ 10.0 g/dL (100 g/L) for women.
  • Positive for surface antigen or anti- virus antibody
  • Abnormal Free T4
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    dapagliflozin 5mg

    dapagliflozin tablet 5mg

    Drug: Dapagliflozin 5mg

  • Experimental
    dapagliflozin 10mg

    dapagliflozin tablet 10mg

    Drug: Dapagliflozin 10mg

  • Placebo comparator
    Placebo

    dapagliflozin tablet 5mg placebo or 10 mg placebo

    Drug: Placebo tablet

Interventions

  • Dapagliflozin, a blood glucose lowering drug. Oral dose

  • Dapagliflozin, a blood glucose lowering drug. Oral dose

  • DrugPlacebo tablet

    Placebo tablet. Oral dose

06

What researchers measure

Primary outcomes

  1. Dapagliflozin Maximum Observed Plasma Concentration (Cmax) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set

    Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).

    Time frame: Day 1-7

  2. Dapagliflozin Minimum Observed Plasma Concentration (Cmin) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set

    Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).

    Time frame: Day 1-7

  3. Dapagliflozin Time of Maximum Observed Plasma Concentration (Tmax) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set

    Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).

    Time frame: Day 1-7

  4. Dapagliflozin Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration AUC(0-T) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set

    Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).

    Time frame: Day 1-7

  5. Dapagliflozin 3-O-Glucuronide Maximum Observed Plasma Concentration (Cmax) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set

    Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).

    Time frame: Day 1-7

  6. Dapagliflozin 3-O-Glucuronide Minimum Observed Plasma Concentration (Cmin) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set

    Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).

    Time frame: Day 1-7

  7. Dapagliflozin 3-O-Glucuronide Time of Maximum Observed Plasma Concentration (Tmax) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set

    Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).

    Time frame: Day 1-7

  8. Dapagliflozin 3-O-Glucuronide Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration AUC(0-T) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set

    Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).

    Time frame: Day 1-7

  9. Dapagliflozin Ratio of Metabolite to Parent AUC of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set

    Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).

    Time frame: Day 1-7

  10. 24-hour Urinary Glucose (g/24h) Mean Change From Baseline on Day 7 - Pharmacodynamic (PD) Set

    The 24-hour period is defined based on the morning void, from the first morning void to the one of the next day.

    Time frame: Baseline (the last available assessment prior to the first dose of study medication), Day 7

Secondary outcomes

  1. Total Daily Insulin (IU) Percent Change From Baseline to Day 7 - Pharmacodynamic (PD) Set

    Total daily insulin dose is defined as the sum of all insulin doses (basal+bolus+premixed) for each day. Mean percent change from baseline was calculated using the geometric mean back-transformed from the results calculated under the logarithm transformation.

    Time frame: Baseline (the last available assessment on or prior to the first dose of study medication), Day 7

  2. Daily Basal Insulin (IU) Percent Change From Baseline to Day 7 - Pharmacodynamic (PD) Set

    Mean percent change from baseline was calculated using the geometric mean back-transformed from the results calculated under the logarithm transformation.

    Time frame: Baseline (the last available assessment on or prior to the first dose of study medication), Day 7

  3. Daily Bolus Insulin (IU) Percent Change From Baseline to Day 7 - Pharmacodynamic (PD) Set

    Mean percent change from baseline was calculated using the geometric mean back-transformed from the results calculated under the logarithm transformation.

    Time frame: Baseline (the last available assessment on or prior to the first dose of study medication), Day 7

  4. Fasting Plasma Glucose (FPG) (mg/dL) Change From Baseline to Day 7 - Pharmacodynamic (PD) Set

    Time frame: Baseline (the last available assessment on or prior to the first dose of study medication), Day 7

  5. Seated Systolic Blood Pressure (mmHG) Change From Baseline to Day 7 - Pharmacodynamic (PD) Set

    Time frame: Baseline (the last available assessment on or prior to the first dose of study medication), Day 7

07

Results

Posted Jan 18, 2019

Participant flow

26 October 2015 to 04 June 2016, Japan, patients with type 1 diabetes mellitus.

Participant flow — Overall Study
MilestonePlacebo + InsulinDapagliflozin 5mg + InsulinDapagliflozin 10 mg + Insulin
Started141414
Completed141414
Not completed000

Outcome measures

PrimaryDapagliflozin Maximum Observed Plasma Concentration (Cmax) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set

Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).

Time frame:
Day 1-7
Reported as:
Geometric mean · ng/mL
Dapagliflozin Maximum Observed Plasma Concentration (Cmax) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set
ng/mLDapagliflozin 5mg + InsulinDapagliflozin 10mg + Insulin
Dapagliflozin Maximum Observed Plasma Concentration (Cmax) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set69.31 ± 26.42162.09 ± 26.03
PrimaryDapagliflozin Minimum Observed Plasma Concentration (Cmin) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set

Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).

Time frame:
Day 1-7
Reported as:
Geometric mean · ng/mL
Dapagliflozin Minimum Observed Plasma Concentration (Cmin) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set
ng/mLDapagliflozin 5mg + InsulinDapagliflozin 10mg + Insulin
Dapagliflozin Minimum Observed Plasma Concentration (Cmin) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set3.40 ± 80.145.71 ± 52.36
PrimaryDapagliflozin Time of Maximum Observed Plasma Concentration (Tmax) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set

Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).

Time frame:
Day 1-7
Reported as:
Median · hours
Dapagliflozin Time of Maximum Observed Plasma Concentration (Tmax) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set
hoursDapagliflozin 5mg + InsulinDapagliflozin 10mg + Insulin
Dapagliflozin Time of Maximum Observed Plasma Concentration (Tmax) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set2.00 ± 52.362.00 (1.00 to 3.00)
PrimaryDapagliflozin Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration AUC(0-T) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set

Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).

Time frame:
Day 1-7
Reported as:
Geometric mean · ng*h/mL
Dapagliflozin Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration AUC(0-T) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set
ng*h/mLDapagliflozin 5mg + InsulinDapagliflozin 10mg + Insulin
Dapagliflozin Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration AUC(0-T) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set322.72 ± 44.69670.01 ± 36.92
PrimaryDapagliflozin 3-O-Glucuronide Maximum Observed Plasma Concentration (Cmax) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set

Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).

Time frame:
Day 1-7
Reported as:
Geometric mean · ng/mL
Dapagliflozin 3-O-Glucuronide Maximum Observed Plasma Concentration (Cmax) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set
ng/mLDapagliflozin 5mg + InsulinDapagliflozin 10mg + Insulin
Dapagliflozin 3-O-Glucuronide Maximum Observed Plasma Concentration (Cmax) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set61.88 ± 31.95136.62 ± 31.96
PrimaryDapagliflozin 3-O-Glucuronide Minimum Observed Plasma Concentration (Cmin) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set

Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).

Time frame:
Day 1-7
Reported as:
Geometric mean · ng/mL
Dapagliflozin 3-O-Glucuronide Minimum Observed Plasma Concentration (Cmin) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set
ng/mLDapagliflozin 5mg + InsulinDapagliflozin 10mg + Insulin
Dapagliflozin 3-O-Glucuronide Minimum Observed Plasma Concentration (Cmin) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set3.89 ± 56.436.25 ± 35.45
PrimaryDapagliflozin 3-O-Glucuronide Time of Maximum Observed Plasma Concentration (Tmax) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set

Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).

Time frame:
Day 1-7
Reported as:
Median · hours
Dapagliflozin 3-O-Glucuronide Time of Maximum Observed Plasma Concentration (Tmax) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set
hoursDapagliflozin 5mg + InsulinDapagliflozin 10mg + Insulin
Dapagliflozin 3-O-Glucuronide Time of Maximum Observed Plasma Concentration (Tmax) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set2.00 ± 52.362.00 (1.00 to 3.00)
PrimaryDapagliflozin 3-O-Glucuronide Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration AUC(0-T) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set

Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).

Time frame:
Day 1-7
Reported as:
Geometric mean · ng*h/mL
Dapagliflozin 3-O-Glucuronide Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration AUC(0-T) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set
ng*h/mLDapagliflozin 5mg + InsulinDapagliflozin 10mg + Insulin
Dapagliflozin 3-O-Glucuronide Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration AUC(0-T) of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set345.87 ± 29.32675.50 ± 23.66
PrimaryDapagliflozin Ratio of Metabolite to Parent AUC of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set

Serial blood samples for determination of study drug were collected predose Day 1, Day 7 (60 minutes prior to dose), Day 7 (0, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose).

Time frame:
Day 1-7
Reported as:
Geometric mean · ratio
Dapagliflozin Ratio of Metabolite to Parent AUC of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set
ratioDapagliflozin 5mg + InsulinDapagliflozin 10mg + Insulin
Dapagliflozin Ratio of Metabolite to Parent AUC of 7 Days Repeated Doses of Dapagliflozin - Pharmacokinetic (PK) Set0.75 ± 44.260.70 ± 30.40
Primary24-hour Urinary Glucose (g/24h) Mean Change From Baseline on Day 7 - Pharmacodynamic (PD) Set

The 24-hour period is defined based on the morning void, from the first morning void to the one of the next day.

Time frame:
Baseline (the last available assessment prior to the first dose of study medication), Day 7
Reported as:
Mean · g/24-hour
24-hour Urinary Glucose (g/24h) Mean Change From Baseline on Day 7 - Pharmacodynamic (PD) Set
g/24-hourPlacebo + InsulinDapagliflozin 5mg+ InsulinDapagliflozin 10mg + Insulin
24-hour Urinary Glucose (g/24h) Mean Change From Baseline on Day 7 - Pharmacodynamic (PD) Set-6.16 ± 30.33796.55 ± 30.083101.28 ± 20.129
SecondaryTotal Daily Insulin (IU) Percent Change From Baseline to Day 7 - Pharmacodynamic (PD) Set

Total daily insulin dose is defined as the sum of all insulin doses (basal+bolus+premixed) for each day. Mean percent change from baseline was calculated using the geometric mean back-transformed from the results calculated under the logarithm transformation.

Time frame:
Baseline (the last available assessment on or prior to the first dose of study medication), Day 7
Reported as:
Mean · percent chagne
Total Daily Insulin (IU) Percent Change From Baseline to Day 7 - Pharmacodynamic (PD) Set
percent chagnePlacebo + InsulinDapagliflozin 5mg+ InsulinDapagliflozin 10mg + Insulin
Total Daily Insulin (IU) Percent Change From Baseline to Day 7 - Pharmacodynamic (PD) Set-4.97 ± 5.280-36.86 ± 3.324-39.13 ± 2.675
SecondaryDaily Basal Insulin (IU) Percent Change From Baseline to Day 7 - Pharmacodynamic (PD) Set

Mean percent change from baseline was calculated using the geometric mean back-transformed from the results calculated under the logarithm transformation.

Time frame:
Baseline (the last available assessment on or prior to the first dose of study medication), Day 7
Reported as:
Mean · percent change
Daily Basal Insulin (IU) Percent Change From Baseline to Day 7 - Pharmacodynamic (PD) Set
percent changePlacebo + InsulinDapagliflozin 5mg+ InsulinDapagliflozin 10mg + Insulin
Daily Basal Insulin (IU) Percent Change From Baseline to Day 7 - Pharmacodynamic (PD) Set-16.75 ± 7.215-36.74 ± 5.671-39.63 ± 3.466
SecondaryDaily Bolus Insulin (IU) Percent Change From Baseline to Day 7 - Pharmacodynamic (PD) Set

Mean percent change from baseline was calculated using the geometric mean back-transformed from the results calculated under the logarithm transformation.

Time frame:
Baseline (the last available assessment on or prior to the first dose of study medication), Day 7
Reported as:
Mean · percent change
Daily Bolus Insulin (IU) Percent Change From Baseline to Day 7 - Pharmacodynamic (PD) Set
percent changePlacebo + InsulinDapagliflozin 5mg+ InsulinDapagliflozin 10mg + Insulin
Daily Bolus Insulin (IU) Percent Change From Baseline to Day 7 - Pharmacodynamic (PD) Set4.56 ± 5.905-36.06 ± 4.238-39.89 ± 3.367
SecondaryFasting Plasma Glucose (FPG) (mg/dL) Change From Baseline to Day 7 - Pharmacodynamic (PD) Set
Time frame:
Baseline (the last available assessment on or prior to the first dose of study medication), Day 7
Reported as:
Mean · mg/dL
Fasting Plasma Glucose (FPG) (mg/dL) Change From Baseline to Day 7 - Pharmacodynamic (PD) Set
mg/dLPlacebo + InsulinDapagliflozin 5mg+ InsulinDapagliflozin 10mg + Insulin
Fasting Plasma Glucose (FPG) (mg/dL) Change From Baseline to Day 7 - Pharmacodynamic (PD) Set11.0 ± 41.31-10.4 ± 62.10-13.1 ± 44.69
SecondarySeated Systolic Blood Pressure (mmHG) Change From Baseline to Day 7 - Pharmacodynamic (PD) Set
Time frame:
Baseline (the last available assessment on or prior to the first dose of study medication), Day 7
Reported as:
Mean · mmHG
Seated Systolic Blood Pressure (mmHG) Change From Baseline to Day 7 - Pharmacodynamic (PD) Set
mmHGPlacebo + InsulinDapagliflozin 5mg+ InsulinDapagliflozin 10mg + Insulin
Seated Systolic Blood Pressure (mmHG) Change From Baseline to Day 7 - Pharmacodynamic (PD) Set-3.1 ± 7.81-2.1 ± 7.711.5 ± 10.66

Adverse events

Collected over Non-serious adverse event (AE): onset on or after the 1st day of dose up to on or prior to the last day of dose plus 4 days. Serious AE: onset on or after the 1st day of dose up to on or prior to the last day of dose plus 30 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo + Insulin0/14 (0%)0/14 (0%)1/14 (7.1%)
Dapagliflozin 5mg + Insulin0/14 (0%)0/14 (0%)2/14 (14.3%)
Dapagliflozin 10 mg + Insulin0/14 (0%)0/14 (0%)5/14 (35.7%)
Most frequent other events
Most frequent other events
EventPlacebo + InsulinDapagliflozin 5mg + InsulinDapagliflozin 10 mg + Insulin
THIRSTGeneral disorders0/141/144/14
URINE OUTPUT INCREASEDInvestigations0/140/142/14
POLLAKIURIARenal and urinary disorders0/142/142/14
MALAISEGeneral disorders0/140/141/14
MUMPSInfections and infestations0/140/141/14
SINUSITISInfections and infestations0/140/141/14
INFLUENZAInfections and infestations1/140/140/14
DECREASED APPETITEMetabolism and nutrition disorders0/140/141/14

Baseline characteristics

Randomized Subjects

Age, Continuous
Age, Continuous(years)Placebo + InsulinDapagliflozin 5mg + InsulinDapagliflozin 10 mg + InsulinTotal
Mean42.6 ± 10.6237.0 ± 10.0537.1 ± 10.2138.9 ± 10.38
Age, Customized
Age, Customized(Participants)Placebo + InsulinDapagliflozin 5mg + InsulinDapagliflozin 10 mg + InsulinTotal
<45 Years10101030
>=45 Years44412
Sex: Female, Male
Sex: Female, Male(Participants)Placebo + InsulinDapagliflozin 5mg + InsulinDapagliflozin 10 mg + InsulinTotal
Female116724
Male38718
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo + InsulinDapagliflozin 5mg + InsulinDapagliflozin 10 mg + InsulinTotal
Asian14141442
Region of Enrollment
Region of Enrollment(Participants)Placebo + InsulinDapagliflozin 5mg + InsulinDapagliflozin 10 mg + InsulinTotal
Japan14141442
Duration of Type 1 Diabetes
Duration of Type 1 Diabetes(years)Placebo + InsulinDapagliflozin 5mg + InsulinDapagliflozin 10 mg + InsulinTotal
Mean16.89 ± 10.53015.94 ± 9.23514.69 ± 12.36815.84 ± 10.561
Hemoglobin A1c (HbA1c)%
Hemoglobin A1c (HbA1c)%(percent of hemoglobin)Placebo + InsulinDapagliflozin 5mg + InsulinDapagliflozin 10 mg + InsulinTotal
Mean8.13 ± 0.8357.91 ± 0.6107.89 ± 0.5537.98 ± 0.669
Fasting Plasma Glucose (FPG)
Fasting Plasma Glucose (FPG)(mg/dL)Placebo + InsulinDapagliflozin 5mg + InsulinDapagliflozin 10 mg + InsulinTotal
Mean134.00 ± 63.898142.93 ± 49.930133.36 ± 42.239136.76 ± 51.675

1 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Fukuoka-shi, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2015, a primary completion of Jun 2016 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2019, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2015
First posted
Oct 21, 2015
Start
Oct 2015
Primary completionActual
Jun 2016
CompletionActual
Jun 2016
Results first posted
Jan 18, 2019
Last update
Jan 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02582840
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Oct 21, 2015
Start date
Oct 2015
Primary completion
Jun 2016
Completion
Jun 2016
Results posted
Jan 18, 2019
Last update
Jan 18, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapagliflozin

Start the discussion